10-K: Longduoduo Company Limited Reports Significant Revenue Growth in Annual Filing

Longduoduo Company Limited's annual report reveals a substantial increase in revenue, primarily driven by its sales agency business, alongside ongoing efforts to establish its brand and expand service offerings.

Summary

• Longduoduo Company Limited's annual report for the fiscal year ended June 30, 2024, shows a significant increase in total revenue to $7,389,842, a 94% increase compared to $3,818,560 in the previous year.
• The company's revenue is primarily derived from commissions earned as a sales agent for Inner Mongolia Honghai Health Management Co., Ltd., which accounted for over 95% of the total revenue.
• Service revenue from direct sales of healthcare services decreased by almost 82% compared to the previous year, totaling $327,599.
• The company's gross profit increased to $7,216,493, a 124% increase from $3,226,675 in the previous year.
• Operating expenses increased to $5,190,352, primarily due to increased advertising and promotion expenses of $3,338,737.
• Net income for the year was $1,363,278, a significant improvement from $21,085 in the previous year.
• The company's cash and cash equivalents stood at $1,404,042 as of June 30, 2024.
• The company has a working capital of $395,609, with $713,360 in customer prepayments, most of which has been used to pay ongoing expenses.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and a significant improvement in net income, indicating positive financial performance. However, there are also significant risks and challenges, including reliance on a single customer, regulatory uncertainties, and the need for additional capital. The sentiment is therefore cautiously optimistic.

Positives

• The company experienced a substantial increase in revenue and gross profit.
• The company achieved a significant turnaround in net income, moving from a small profit to a substantial profit.
• The company has a strong cash position of $1,404,042.
• The company has established a sales agency agreement with Inner Mongolia Honghai Health Management Co., Ltd. which is generating significant revenue.

Negatives

• The company's service revenue from direct sales decreased by almost 82%.
• The company's operating expenses increased significantly, primarily due to advertising and promotion costs.
• The company has a relatively low working capital of $395,609.
• The company is heavily reliant on a single customer for commission revenue.

Risks

• The company is heavily reliant on its relationship with Inner Mongolia Honghai Health Management Co., Ltd., and termination of this relationship could significantly impact financial results.
• The company faces risks related to the COVID-19 pandemic, which has caused interruptions in business operations.
• The company relies on third-party healthcare service providers and could face liability and reputational harm if these providers perform poorly.
• The company faces competition from major public hospitals and private medical examination companies.
• The company may not be able to effectively manage its planned growth due to limited resources.
• The company may need additional capital, which may not be available on acceptable terms.
• The company's internal controls over financial reporting may not be effective.
• The company's operations are subject to significant regulatory risks in China.
• The company may face difficulties in enforcing legal rights in China.
• The company's stock may be delisted if its auditor is not inspected by the PCAOB for two consecutive years.
• The company may be subject to a variety of laws and regulations in the PRC regarding privacy, data security, cybersecurity, and data protection.
• The company will require the approval of the CSRC before its common stock may become listed on the OTCQB, Nasdaq or any U.S. securities exchange.

Future Outlook

The company plans to expand its service offerings, network coverage, and upgrade service standards to become a leading health management service provider and sales agency in China. The company intends to fund its growth by raising capital through the sale of securities outside of the PRC.

Management Comments

• Management will continue to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products and services.
• Management believes that there are no material inaccuracies or omissions of material fact and, to the best of its knowledge, believes that the consolidated financial statements included in this annual report present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

Industry Context

The company operates in the competitive preventive healthcare market in China, facing competition from major public hospitals and private medical examination companies. The company is focusing on the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.

Comparison to Industry Standards

• The company's shift to a sales agency model, with over 95% of revenue from commissions, is a significant departure from its previous principal sales model.
• The company's gross profit margin of 47% on service revenue is lower than the 67% achieved in the previous year, indicating a change in the business model.
• The company's significant investment in advertising and promotion, totaling $3,338,737, is a strategic move to establish its brand in a competitive market.
• The company's reliance on a single customer for commission revenue is a significant risk, which is not uncommon for companies in the early stages of a sales agency model.
• The company's net income of $1,363,278 is a significant improvement compared to the previous year, but it is important to note that this is largely due to the shift to the sales agency model and the associated increase in revenue.

Management Changes

Corporate Governance

Related Party Transactions

• The company had outstanding balances due to related parties, including $2,233 due to Zhang Liang and $0 due to Zhou Hongxiao as of June 30, 2024.

Stakeholder Impact

• Shareholders may benefit from the company's improved financial performance, but face risks related to regulatory uncertainties and potential delisting.
• Employees may benefit from the company's growth, but face risks related to the company's reliance on a single customer.
• Customers may benefit from the company's expanded service offerings, but face risks related to the quality of third-party service providers.
• Suppliers may benefit from the company's increased revenue, but face risks related to the company's reliance on a single customer.
• Creditors may benefit from the company's improved financial position, but face risks related to the company's reliance on a single customer.

Next Steps

• The company plans to expand its product offerings.
• The company plans to continue to expand its network coverage nationwide.
• The company plans to further upgrade its service standards to enhance the customer experience.
• The company plans to apply for listing on the OTCQB or Nasdaq as soon as it is eligible.

Key Dates

Keywords

healthcare, preventive healthcare, sales agency, commissions, China, Inner Mongolia, medical services, financial results, revenue growth, operating expenses, internal controls, regulatory risks